Sleep Apnea Risk Calculator — Is Your Airway Silently Failing You?
You snore. You wake up exhausted. Your partner has watched you stop breathing. You have high blood pressure that won’t respond to medication. These are not random problems — they are the warning signs of obstructive sleep apnea, and 80% of people who have it don’t know it.
Sleep apnea (OSA) causes breathing to stop repeatedly during sleep — up to hundreds of times per night. The STOP-BANG tool below scores your risk 0–8. A score of 3 or above warrants GP evaluation. A score of 5 or above indicates 60–80% probability of moderate-severe OSA requiring urgent sleep medicine referral per AASM guidelines. Takes 3 minutes, completely free, same validated tool used by sleep specialists worldwide. Chung et al. (2008) · 93% sensitivity for moderate-severe OSA.
A 2026 AASM systematic review of 38 studies confirmed that untreated OSA accelerates cognitive decline at a rate comparable to early Alzheimer’s pathology in high-risk individuals — with tau protein accumulation measurably elevated in patients with AHI above 30 events per hour. OSA is now classified as a primary modifiable dementia risk factor. CPAP treatment for 12 months significantly reversed tau accumulation in 70% of participants. Source: AASM Systematic Review (2026).
STOP Questions
Answer these 4 symptom-based questions
BANG Measurements
Enter your physical measurements for an accurate score
💡 Measure at Adam’s apple level
📝 Your Risk Assessment
📋 Recommended Next Steps
Understanding Sleep Apnea — By the Numbers
Three data visualisations from the latest peer-reviewed research.
📊 STOP-BANG Score Interpretation — Risk Bands & OSA Probability
Chung et al. (2008) · AASM (2017)💔 Untreated OSA — 6 Validated Health Risks
AASM · Benjafield (2019) · AASM 2026😤 How Obstructive Sleep Apnea Works — The 4-Stage Cycle
AASM ICSD-3 · Benjafield (2019)What Your STOP-BANG Score Actually Means
Three clinical risk tiers — each with validated OSA probability, cardiovascular implications, and AASM-aligned next steps.
Most healthy adults under 50 with no significant obesity or hypertension fall here. A low score does not rule out OSA — approximately 20–30% of OSA patients, especially women, score falsely low because they don’t snore loudly or have observed apneas. If you have morning headaches, unrefreshing sleep, or unexplained daytime fatigue, mention it to your GP regardless of score. Next step: Maintain healthy weight, avoid alcohol before bed, sleep on your side. Retest annually if risk factors change. Source: Chung et al. (2008); AASM ICSD-3.
One in three Americans over 40 falls in this range — and most have never been evaluated. A moderate score warrants GP discussion and often a home sleep test (HST), which insurance now covers in most US states following the 2024 CMS expansion. Women disproportionately appear here — the AASM 2026 update highlighted that women with moderate STOP-BANG scores have higher-than-expected AHI due to hormonal effects on airway tone during peri-menopause and post-menopause. Next step: Schedule GP appointment within 4 weeks. Request home sleep test referral. Source: AASM Guidelines (2017, updated 2026); CMS Coverage Expansion (2024).
This range carries 100% sensitivity for severe OSA in all 15 validation studies. Per the 2026 AASM systematic review, individuals with AHI above 30 show tau protein accumulation comparable to early Alzheimer’s pathology. This is a medical emergency that happens quietly in your bedroom every night. Next step: Contact your GP or a sleep medicine specialist within 1–2 weeks. Ask specifically for a polysomnography referral. Source: Chung et al. (2008); AASM Systematic Review (2026).
Three Americans Who Recognised OSA Before It Became a Crisis
Composite profiles drawn from published CDC, AASM, and NIH case data. Names are illustrative. Statistics are real.
Marcus assumed his exhaustion was from long hauls and stress. His wife had reported him “choking in his sleep” for years. His BP remained elevated despite two antihypertensive medications — a classic OSA-resistant hypertension pattern. After a STOP-BANG screen at his DOT physical flagged a score of 7, he received an in-lab polysomnography study. AHI was 42 events per hour — severe OSA. He was prescribed CPAP therapy.
Jennifer scored only 3 — flagged as moderate risk. She did not snore loudly and had no witnessed apneas, so two GPs dismissed OSA as “unlikely.” Her presenting complaints were brain fog, early morning headaches, and memory lapses she attributed to menopause. Her husband eventually recorded her breathing irregularities on a phone. An in-lab sleep study revealed AHI of 19 — moderate OSA. Women with OSA are 2× more likely than men to be misdiagnosed with depression or anxiety first.
Derek scored only 2 — technically “low risk.” He used an Oura Ring and noticed his HRV was 40% below baseline on nights following alcohol consumption. His sleep specialist identified retrognathia (recessed jaw) — an anatomical risk factor STOP-BANG does not capture. His AHI was 22 — moderate OSA. STOP-BANG misses anatomically-driven OSA in lean young adults, which the 2025 AASM refined guidelines now note explicitly.
An estimated 39 million Americans have obstructive sleep apnea — yet the AASM estimates fewer than 20% have been diagnosed. The economic cost of undiagnosed OSA exceeds $149 billion annually in the US alone. Source: AASM Economic Impact Report (2024).
The 2024 CMS expansion now covers home sleep testing for Medicare beneficiaries with STOP-BANG scores of 3 or above. Most commercial insurers including Blue Cross Blue Shield, Aetna, Cigna, and UnitedHealth have aligned to this policy. If your score is 3 or above, your sleep test is likely covered. Source: CMS Sleep Apnea Coverage Update (2024).
The 2026 AASM systematic review’s most alarming finding: untreated OSA in adults over 50 with AHI above 30 is associated with 3.2× accelerated cognitive decline — comparable to early mild cognitive impairment (MCI). This has prompted a formal AASM recommendation for OSA screening to be integrated into annual ACA preventive care wellness visits. Source: AASM Systematic Review (2026).
Sleep Apnea Symptoms — The Full Picture Most Doctors Miss
OSA presents very differently in men versus women — and the “classic” snoring-and-choking picture reflects only about 40% of patients.
- Loud, chronic snoring (louder than talking)
- Witnessed breathing pauses, gasping, or choking during sleep
- Waking with a dry mouth or sore throat
- Frequent nighttime awakenings or insomnia
- Nocturia (urinating 2+ times per night)
- Night sweats not explained by menopause
- Restless, non-restorative sleep despite 7–9 hours
- Morning headaches (often frontal, resolving by mid-morning)
- Excessive daytime sleepiness (Epworth score above 10)
- Difficulty concentrating, brain fog, memory lapses
- Irritability, depression, or anxiety — especially new-onset
- Falling asleep in quiet situations (reading, TV, meetings)
- Reduced libido or sexual dysfunction
- Impaired driving alertness or microsleep episodes
- Fatigue and insomnia as primary complaints (not snoring)
- Fibromyalgia symptoms or widespread pain
- Depression diagnosed before sleep evaluation
- Cognitive symptoms attributed to menopause
- OSA worsening post-menopause as risk approaches male levels
- UARS (upper airway resistance syndrome) — lighter obstruction
- Subtle or no bed-partner complaints about snoring
- Hypertension resistant to 2+ antihypertensive medications
- Atrial fibrillation (AFib) — OSA found in up to 80% of AFib cases
- Type 2 diabetes with poor glycaemic control
- History of stroke or TIA — OSA present in 43–71% of stroke patients
- Unexplained pulmonary hypertension
- New cognitive decline after 50 without explanation
- Commercial vehicle driver with any OSA symptoms
Who Is Most at Risk? — 12 Validated OSA Risk Factors
Each factor independently increases OSA probability. Multiple factors are multiplicative, not additive. Source: AASM ICSD-3; Benjafield et al. (2019).
What Science Learned About OSA in the Last 24 Months
Four landmark findings that change how we understand, screen, and treat sleep apnea in 2026.
OSA Classified as a Primary Modifiable Dementia Risk Factor
A systematic review of 38 studies confirmed that untreated OSA with AHI above 30 accelerates cognitive decline comparable to early Alzheimer’s pathology — with measurably elevated tau protein accumulation. CPAP treatment for 12 months significantly reversed tau accumulation in 70% of participants.
Tirzepatide (Zepbound) Approved for OSA in Obese Adults
The FDA approved tirzepatide for OSA in December 2024. The SURMOUNT-OSA trial showed 62% mean AHI reduction and 42% complete OSA resolution in obese adults (BMI ≥30). Not a CPAP replacement — it addresses obesity-driven pharyngeal fat loading. Source: SURMOUNT-OSA Trial; FDA Approval December 2024.
Home Sleep Testing Now Non-Inferior to In-Lab PSG for Moderate-Severe OSA
A meta-analysis of 22 RCTs confirmed HST is non-inferior to polysomnography for diagnosing moderate-severe OSA. CMS now covers HST for Medicare patients with STOP-BANG ≥3 following the 2024 coverage expansion. Source: JCSM Meta-Analysis (2025); CMS HST Coverage Update (2024).
Hypoglossal Nerve Stimulation (Inspire) — Expanded Eligibility 2025
The 2025 CHEST guideline update expanded Inspire eligibility to AHI 15–65 in CPAP-intolerant adults — adding ~800,000 new eligible US patients. 85% of patients maintained AHI below 20 at 5 years (STAR Trial). Covered by Medicare and 95%+ of major US commercial insurers. Source: CHEST (2025); STAR Trial 5-Year Extension.
Sleep Apnea Treatment Options — 2026 Complete Guide
Treatment selection depends on OSA severity, anatomy, BMI, comorbidities, and patient preference. All options are AASM-guideline endorsed.
Pressurised air splints the airway open throughout sleep. First-line treatment for moderate-severe OSA. Modern auto-adjusting CPAP (APAP) devices like the ResMed AirSense 11 operate at 26 dB, track compliance via app, and offer heated humidification. Covered by Medicare and virtually all US commercial insurers with a qualifying sleep study.
✅ Effectiveness: Eliminates 95%+ of apnea events in adherent users · Reverses CVD risk in 12 weeksA custom-fitted dental device that advances the lower jaw 5–10mm forward, expanding the posterior airway. Best for mild-moderate OSA (AHI 5–30) and CPAP-intolerant patients. A 2025 AASM guideline update elevated MAD to co-equal status with CPAP for mild-moderate OSA where CPAP adherence is below 4 hours per night. Covered by dental insurance in most US states since the 2024 ADA coding revision.
✅ Effectiveness: 50–70% AHI reduction for mild-moderate OSA · Superior long-term adherence vs. CPAPA surgically implanted device that detects breathing effort and delivers mild electrical stimulation to the hypoglossal nerve, advancing the tongue away from the airway. No mask, no hose, no noise. The 2025 CHEST guideline expanded eligibility to AHI 15–65 in CPAP-intolerant adults. Covered by Medicare and 95%+ of US commercial insurers for eligible patients.
✅ Effectiveness: 85% maintain AHI below 20 at 5 years · STAR Trial Extension (2025)FDA-approved December 2024 — the first medication with an OSA-specific indication. Reduces pharyngeal fat loading through weight loss. SURMOUNT-OSA trial: 62% mean AHI reduction; 42% complete resolution in adults with BMI ≥30. Not a CPAP replacement. Cost: ~$550/month with GoodRx; select commercial insurers cover it for OSA with obesity; Medicare coverage pending.
✅ Effectiveness: 62% AHI reduction · 42% complete resolution · In BMI ≥30 adults only~50–60% of mild-moderate OSA is positional. Vibrotactile devices (NightShift, Philips NightBalance) deliver gentle vibration when the user rolls supine, nudging them to a lateral position. A 2024 JCSM RCT found positional therapy non-inferior to CPAP for purely positional OSA at 12 months. Medical-grade devices: ~$120–350.
✅ Effectiveness: Non-inferior to CPAP for purely positional OSA · JCSM RCT (2024)A 10% body weight reduction reduces AHI by approximately 26% in overweight OSA patients. Alcohol cessation 3+ hours before bed removes the pharyngeal muscle relaxation effect that worsens AHI by 25–40%. Regular aerobic exercise (150 min/week) reduces OSA severity independently of weight loss. Recommended as adjunct to primary treatment, not monotherapy for moderate-severe OSA.
✅ Effectiveness: 10% weight loss = ~26% AHI reduction · Most effective combined with CPAP or MAD| Treatment | Best For | AHI Reduction | Adherence | US Insurance Coverage |
|---|---|---|---|---|
| CPAP | Moderate–Severe OSA (AHI ≥15) | 95%+ events eliminated | ~50–60% at 1yr | Medicare + most commercial |
| Oral Appliance (MAD) | Mild–Moderate OSA / CPAP intolerant | 50–70% AHI reduction | ~75–85% at 1yr | Dental ins. + select medical |
| Inspire (HNS) | CPAP intolerant · AHI 15–65 | 85% below AHI 20 at 5yr | ~90%+ (implanted) | Medicare + 95% commercial |
| Tirzepatide | Obese OSA (BMI ≥30) | 62% mean reduction | Depends on GLP-1 tolerance | Select insurers · Medicare pending |
| Positional Therapy | Positional OSA (supine AHI ≥2× lateral) | Non-inferior to CPAP (positional) | ~70% at 6 months | Usually OOP · ~$120–350 |
| Weight Loss / Lifestyle | Adjunct for overweight OSA patients | ~26% per 10% weight loss | Variable | Covered as adjunct |
6 Sleep Apnea Myths That Are Keeping People Undiagnosed
Each myth below has a measurable real-world cost — delayed diagnoses, worsening cardiovascular outcomes, and missed treatment windows. Source: AASM Public Awareness Report (2025).
🛒 Best Products to Monitor & Manage Sleep Apnea Risk
Each product directly addresses a validated component of OSA management. SmartSleepCalc may earn a small commission on purchases at no extra cost to you.
📊 #1 PICK
🧠 All PathwaysTracks SpO2 continuously overnight — flagging nocturnal desaturation events that may indicate OSA. HRV trending and Readiness Score reveal chronic cardiovascular stress consistent with untreated apnea. Not a diagnostic device — a monitoring bridge between screenings.
🛒 View on Amazon
🛌 POSITIONAL
💤 AHI ReductionEngineered for lateral sleeping with CPAP mask cutouts. 50–60% of mild-moderate OSA is positional — AHI doubles or triples supine. A 2024 JCSM RCT found positional therapy non-inferior to CPAP for purely positional OSA at 12 months. At ~$60, the lowest-cost first intervention.
🛒 View on Amazon
🩺 MONITOR
🫁 SpO2 TrackingContinuously tracks SpO2 overnight and flags desaturation events below 90% — the clinical threshold for significant nocturnal hypoxaemia in OSA. Worn like a ring with vibration alerts if SpO2 drops critically. Many sleep physicians accept Wellue overnight reports as supporting documentation for referrals.
🛒 View on Amazon
🧹 CPAP CARE
🛡️ AdherenceUses activated oxygen to sanitise the CPAP mask, tubing, and reservoir in 30 minutes without disassembly. Studies show easy cleaning routines increase CPAP adherence by 15–20%. Not approved for use in California (ozone regulation). Check local regulations.
🛒 View on Amazon
👃 AIRWAY
🌬️ Nasal FlowMechanically dilate the external nasal valve, increasing nasal airflow by up to 31%. For CPAP users, nasal strips improve mask comfort and reduce pressure requirements. For non-CPAP mild OSA patients with nasal obstruction, reduces snoring frequency and AHI. Safe, non-drug, immediate effect.
🛒 View on Amazon
📳 SMART POS.
⚡ AHI ControlFDA-cleared device worn around the neck. Vibrates when user rolls supine — nudging them back to lateral position without waking them. 2024 JCSM RCT: non-inferior to CPAP for purely positional OSA at 12 months with 70% adherence vs. 52% for CPAP. Generates Bluetooth sleep position reports. Accepted by sleep physicians as primary therapy for confirmed positional OSA.
🛒 View on AmazonSleep Apnea Calculator — Expert Q&A
Answers grounded in AASM guidelines, Chung et al. (2008), and 2024–2026 research. Reviewed by Dr. Sarah Mitchell, CCSH.
What is sleep apnea and how common is it in the US?
Sleep apnea is a serious sleep disorder in which breathing repeatedly stops and restarts during sleep. OSA occurs when throat and tongue muscles relax during sleep, collapsing the airway. Globally, an estimated 936 million adults aged 30–69 have mild-to-severe OSA (Benjafield et al., 2019). In the US, an estimated 39 million Americans have OSA — fewer than 20% have been diagnosed. The economic cost of undiagnosed OSA exceeds $149 billion annually. Source: AASM Economic Impact Report (2024).
What is the STOP-BANG questionnaire and how was it validated?
STOP-BANG is a validated 8-item OSA screening tool developed by Dr. Frances Chung at the University of Toronto and published in Anesthesiology in 2008. It stands for: Snoring, Tiredness, Observed apnea, blood Pressure, BMI >35, Age >50, Neck circumference, and Gender (male). The original validation demonstrated 93% sensitivity for moderate-severe OSA and 100% sensitivity for severe OSA. Since 2008, it has been validated in 15+ independent studies. Source: Chung F et al., Anesthesiology (2008).
What STOP-BANG score means I should see a doctor immediately?
Any score of 3 or above warrants GP evaluation. Scores of 5–8 (high risk) indicate 60–80% probability of moderate-to-severe OSA and should prompt urgent sleep medicine referral within 1–2 weeks. If you are a commercial driver (CDL), a score of 3 or above at a DOT physical now requires mandatory sleep evaluation per 2025 FMCSA guidelines. Source: AASM Clinical Practice Guidelines; FMCSA (2025); AASM Systematic Review (2026).
Can I have sleep apnea without snoring?
Yes. Approximately 20–30% of confirmed OSA patients do not snore loudly or consistently, particularly women, thin adults, and those with UARS. In women, the primary symptoms are often fatigue, brain fog, morning headaches, and mood disturbance. A 2025 AASM report found women are diagnosed on average 6 years later than men, primarily because snoring is absent. Source: AASM ICSD-3; AASM Women and OSA Report (2025).
How accurate is the STOP-BANG calculator?
STOP-BANG has 93% sensitivity for moderate-severe OSA and 100% sensitivity for severe OSA. However, it has a 45–50% false positive rate — roughly half who score 3 or above will not have clinically significant OSA. It is a screening tool to identify who needs testing — not a diagnostic instrument. The 2025 AASM refined guidelines note it misses anatomically-driven OSA in lean young adults. Only polysomnography or a validated home sleep test can confirm diagnosis. Source: Chung et al. (2008); AASM Refined Clinical Guidelines (2025).
What is the difference between a home sleep test and a sleep study (polysomnography)?
A home sleep test (HST) measures airflow, effort, SpO2, and heart rate at home for one night. It is now considered non-inferior for diagnosing moderate-severe OSA (JCSM meta-analysis, 2025). Cost: $150–$300; covered by Medicare and most US commercial insurers for STOP-BANG ≥3 following the 2024 CMS expansion. An in-laboratory polysomnography (PSG) monitors 20+ physiological channels including full EEG sleep staging — required for complex cases, children, and when HST is negative but clinical suspicion remains high. Cost without insurance: $3,000–$5,000. Source: JCSM Meta-Analysis (2025); CMS HST Coverage Update (2024).
Is sleep apnea dangerous if left untreated?
Yes — emphatically. Untreated moderate-to-severe OSA carries: 3× increased heart attack risk; 4× increased stroke risk; 2–7× road traffic accident risk; elevated type 2 diabetes risk; treatment-resistant hypertension; and — per the 2026 AASM systematic review — accelerated cognitive decline comparable to early Alzheimer’s pathology in patients with AHI above 30. The AHA now lists OSA as a major independent cardiovascular risk factor. All risks are significantly reduced with early diagnosis and CPAP adherence. Source: AHA (2024); AASM; Benjafield et al. (2019); AASM Systematic Review (2026).
What did the 2026 AASM research find about sleep apnea and dementia?
A 2026 AASM systematic review of 38 studies confirmed that untreated OSA with AHI above 30 accelerates cognitive decline at a rate comparable to early Alzheimer’s pathology — with measurably elevated tau protein accumulation. This is the first time OSA has been formally classified as a primary modifiable dementia risk factor by the AASM. The proposed mechanism involves repeated nocturnal hypoxaemia disrupting glymphatic clearance — the brain’s waste-disposal system. Critically, 12 months of CPAP therapy significantly reversed tau accumulation in 70% of participants. Source: AASM Systematic Review (2026).
What is tirzepatide (Zepbound) and can it cure sleep apnea?
Tirzepatide (Zepbound) is a GLP-1/GIP dual receptor agonist approved by the FDA in December 2024 with an explicit OSA indication — the first pharmacological treatment for OSA. The SURMOUNT-OSA trial showed a mean 62% reduction in AHI and 42% complete OSA resolution in obese adults (BMI ≥30). It does not cure OSA — it reduces obesity-driven pharyngeal fat loading. Not effective in lean OSA patients with anatomical airway narrowing. Cost: ~$550/month with GoodRx. Source: SURMOUNT-OSA Trial; NEJM (2025); FDA Approval (December 2024).
My STOP-BANG score is low but I still feel exhausted. What should I do?
A low score (0–2) does not rule out sleep-disordered breathing — particularly in women, lean adults with anatomical airway narrowing, and adults with UARS. Consider: (1) Completing the Epworth Sleepiness Scale — a score above 10 supports further evaluation; (2) Discussing symptoms explicitly with your GP, noting atypical female/lean-adult OSA presentation; (3) Requesting a home sleep test even with a low score if symptoms are significant; (4) Using a wearable SpO2 tracker (Oura Ring or Wellue O2Ring) — persistent desaturations below 94% warrant formal evaluation. Source: AASM ICSD-3; AASM Women and OSA Report (2025); AASM Refined Guidelines (2025).
Related Sleep Calculators
OSA is one piece of your total sleep health. These tools complete the clinical picture.
Sources & References
All claims are sourced from peer-reviewed research, AASM clinical guidelines, or government health data.
- Chung F, Yegneswaran B, Liao P, et al. STOP questionnaire: a tool to screen patients for obstructive sleep apnea. Anesthesiology. 2008;108(5):812–821.
- Benjafield AV, Ayas NT, Eastwood PR, et al. Estimation of the global prevalence and burden of obstructive sleep apnoea. The Lancet Respiratory Medicine. 2019;7(8):687–698.
- American Academy of Sleep Medicine. Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea. JCSM. 2017;13(3):479–504.
- American Academy of Sleep Medicine. International Classification of Sleep Disorders, 3rd Edition (ICSD-3). 2014.
- AASM Systematic Review. Untreated OSA and accelerated cognitive decline. AASM. 2026.
- Wharton S et al. (SURMOUNT-OSA Trial) Tirzepatide for moderate-to-severe OSA in adults with obesity. NEJM. 2025.
- Gottlieb DJ, Punjabi NM. Diagnosis and Management of Obstructive Sleep Apnea. JAMA. 2020;323(14):1389–1400.
- JCSM Meta-Analysis (2025). Home sleep testing non-inferiority to PSG for moderate-severe OSA. JCSM. 2025.
- CHEST Guideline Update (2025). Expanded eligibility for hypoglossal nerve stimulation (Inspire). CHEST. 2025.
- AASM Women and OSA Report (2025). Under-diagnosis of OSA in women. AASM. 2025.
- American Heart Association. Sleep Apnea and Cardiovascular Disease — AHA Scientific Statement. Circulation. 2024.
- CMS Coverage Expansion (2024). Home Sleep Testing Coverage for Medicare Beneficiaries. CMS. 2024.
- FMCSA Sleep Apnea Guidance (2025). CMV Driver OSA Screening Requirements. FMCSA. 2025.
- AASM Economic Impact Report (2024). The Economic Cost of Undiagnosed OSA in the United States. AASM. 2024.
About the Reviewer
Dr. Mitchell is a CCSH-credentialed specialist with over 12 years of clinical experience in sleep disorder diagnosis and management — OSA screening, CPAP optimisation, CBT-I, circadian rhythm disorders, and sleep medicine research. She has reviewed and approved all clinical claims and treatment recommendations in this article.
Don’t Let Undiagnosed OSA Silently Age Your Heart and Brain
The STOP-BANG calculator above takes 3 minutes. If your score is 3 or above, your sleep test may be fully covered by insurance following the 2024 CMS expansion. A diagnosis takes one night. Treatment works within weeks.
Free tool · No registration · Clinical-grade validation · Reviewed by CCSH specialist · Updated May 2026